|
WO2016109802A1
|
|
Site-specific conjugation through glycoproteins linkage and method thereof
|
|
TW201524998A
|
|
Anti-VEGF antibodies and use thereof
|
|
US2015184215A1
|
|
Development of the soluble recombinant crm197 production by e. coli
|
|
US2016068595A1
|
|
Humanized antibody against interleukin-20 and treatment for inflammatory diseases
|
|
US2014178360A1
|
|
Pyrimidine compounds as mTOR and PI3K inhibitors
|
|
CN104800291A
|
|
Magnolia officinalis extract, preparation method and uses thereof
|
|
CN105026425A
|
|
Anti-granulysin antibodies and methods of use thereof
|
|
TW201524530A
|
|
Magnolia extracts and preparation methods and uses thereof
|
|
US2015183884A1
|
|
Alpha-enolase specific antibodies and methods of uses in cancer therapy
|
|
WO2015094330A1
|
|
Alpha-enolase specific antibodies and methods of uses in cancer therapy
|
|
US2015158854A1
|
|
Quinazoline compounds, method for preparing the same and use thereof
|
|
TW201418208A
|
|
Glp-1 potentiators and their applications
|
|
TW201434472A
|
|
Antrodia cinnamomea extract for treating lung cancer and preparation method thereof
|
|
TW201429471A
|
|
Composition for preventing or treating airway disease
|
|
TW201428003A
|
|
Bispecific t-cell activator antibody
|
|
EP2797958A1
|
|
Light chain-bridged bispecific antibody
|
|
CN104144949A
|
|
Bispecific t-cell activator antibody
|
|
TW201341389A
|
|
Heterocyclic pyrazole compounds, method for preparing the same and use thereof
|
|
TW201326129A
|
|
Quinazoline compounds as kinase inhibitors and uses thereof
|
|
TW201300359A
|
|
Novel tubulin inhibitors
|
